Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
08:00am, Monday, 27'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it wi
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options If you are a long-term sto
Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy
10:02am, Thursday, 23'rd Oct 2025
Geron Corporation (GERN) is rated BUY due to strong early RYTELO sales, robust financials, and an undervalued stock price near 52-week lows. RYTELO, recently FDA-approved for lower-risk MDS, is drivin
Geron Corporation (NASDAQ:GERN) Given Average Rating of “Hold” by Analysts
02:32am, Thursday, 23'rd Oct 2025
Shares of Geron Corporation (NASDAQ: GERN - Get Free Report) have been given an average rating of "Hold" by the eight analysts that are covering the stock, MarketBeat Ratings reports. Two research ana
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:32pm, Monday, 20'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025
Geron Corporation Announces Executive Leadership Transitions and Appointments
04:34pm, Monday, 13'th Oct 2025
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commerc
Making Money In Biotech Stocks
05:00pm, Thursday, 09'th Oct 2025
How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 18'th Sep 2025
FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an agg
Geron to Participate in the 2025 Wells Fargo Healthcare Conference
04:05pm, Wednesday, 27'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 18'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000
Geron Corporation Investors: Company Investigated by the Portnoy Law Firm
05:23pm, Thursday, 14'th Aug 2025
Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN)
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 08'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to
Geron: I Think We've Seen This Movie Before
09:30am, Friday, 08'th Aug 2025
Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has alre
Geron Corporation (GERN) Q2 2025 Earnings Call Transcript
03:01pm, Wednesday, 06'th Aug 2025
Geron Corporation (NASDAQ:GERN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim
